Catalyst Pharmaceuticals and Novavax have had tough go of it in May. Could better days be close at hand?
News & Analysis: Novavax
Novavax's proposed reverse split has investors on edge.
Novavax's first-quarter earnings report didn't provide the answers investors were looking for.
NVAX earnings call for the period ending March 31, 2019.
Investors' optimism about the prospects for the biotech's experimental vaccines appears to be increasing.
Novavax needs a deep-pocketed partner soon.
The beleaguered biotech is down but not out.
NVAX earnings call for the period ending December 31, 2018.
Novavax's latest clinical failure may prove to difficult to overcome.
These biopharmaceutical startups have been losing their investors' money for decades.